Yesterday, countless newly sent newsletter included the recommendation for traders to put MRES stock on their watch lists for the session today. It is not certain if that will happen as the promotional campaign is running throughout the whole January, and considering also that yesterday the stock almost topped its record volume from last October. The number of traded shares exceeded 17.9 million and MRES closed the market at $0.033 for a share with a large 26.92% jump up. Compensation for the new promotions consists of 2.5 million free trading MRES shares.
Yesterday session was also not without the usual alerts, and they were also powered by the announced by the company offer for all of MRES outstanding shares at a price of $0.15 each. According to the press release, the offer comes from a similar to Neuro-Biotech company that is “exclusively contracted by military forces to research and develop new type of medications”.
MRES new quarter report suggests that the PR contains a typing mistake, and one more zero is missing after the decimal point in the share price offer. The company still has no current assets whatsoever, no revenues and no products, and almost all of its long-term assets are intangible. On the other hand, a positive thing is that the announced license agreement with the Russian company Credo-TM has been confirmed. The agreement was signed at the end of December and Credo-TM has agreed to purchase 500,000 units of MRES “patented products” at a price of $55.
This is basically the only information about that contract mentioned in the SEC filing. It remains under question how, when and with what money MRES plans to manufacture the “units”, having currently no employees and with a President working on the company’s new business whenever his has time and with no compensation.
